Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 1515
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Friedman, H. S. Articles by Reardon, D. Search for Related Content PubMed Articles by Friedman, H. S. Articles by Reardon, D.

Abstract

Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results

Duke Medcl Ctr, Durham, NC; Novartis Pharm Corp, East Hanover, NJ; Duke Med, Durham, NC

1515

In this phase 2 study we evaluated the activity of imatinib mesylate (Gleevec), an inhibitor of the PDGF receptor tyrosine kinase with anti-angiogenic activity and the ability to decrease tumor interstitial pressure, combined with hydroxyurea in the treatment of patients with recurrent malignant glioma. Eligibility criteria include: recurrent malignant glioma; age > 18 years; KPS 60% or greater; less than grade 2 intratumoral hemorrhage; adequate hepatic, renal, and bone marrow function. Hydroxyurea is administered at 500 mg BID while Gleevec is administered at 500 mg BID for patients on enzyme-inducing anticonvulsants (EIAC; phenytoin, carbamazepine and phenobarbitol) and at 400 mg QD for those not on EIAC. A treatment cycle lasted 28 days and evaluations for response were performed after every other cycle. Enrollment includes 64 patients: 32 with recurrent GBM and 32 with recurrent AA/AO. The median age is 46 (range 21 to 68); 55% are male and 45% are on EIAC. All patients had prior XRT and the median number of prior chemotherapy agents was 3 (range, 1–5) while the median number of prior progressions was 2 (range, 1–7). Toxicity has included grade 3 or 4 hematologic events in 20% and 5% respectively, grade 3 edema in 8% and grade 3 LFT abnormalities in 3%. Nine percent of GBM patients achieved a radiographic response while 35% achieved stable disease. Median progression free survival (PFS) for patients with recurrent AA/AO and GBM are 10.9 and 14.4 weeks respectively. At 6 months, 26.3% of GBM patients are progression free. Among heavily pretreated patients with recurrent GBM enrolled on this study, the rate of radiographic response, median PFS and 6-mth PFS rate compare favorably to results achieved with temozolomide in first relapse indicating that a randomized trial of imatinib mesylate plus hydroxyurea versus temozolomide is warranted.

Author Disclosure

Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis

Abstract presentation from the 2005 ASCO Annual Meeting